2.1
Ivacaftor–tezacaftor–elexacaftor (IVA–TEZ–ELX; Kaftrio, Vertex) is indicated 'in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene'.